pharmaxis

Therapeutic products for respiratory diseases

October 2011

Forward Looking Statements

This presentation may contain forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The forward-looking statements contained in this presentation include statements about future financial and operating results, results of our clinical trials, status of our regulatory submissions, possible or assumed future growth opportunities and risks and uncertainties that could affect Pharmaxis' product and products under development. These statements are not guarantees of future performance, involve certain risks, uncertainties and assumptions that are difficult to predict, and are based upon assumptions as to future events that may not prove accurate. Therefore, actual outcomes and results may differ materially from what is expressed herein. There can be no assurance that any forward looking statement will result or be achieved or accomplished. We are not under any duty to update forwardlooking statements unless required by law. This investor presentation is not an offer of the sale of securities.

Company Overview

Objective	The development of products for respiratory diseases			
Lead products	Aridol: •assessment of asthma and COPI			
	• ?	approved & launched in major markets		
	Bronchitol for cystic fibrosis: •a	approved in Australia		
	•1	recommended for approval in EU		
	٠١	US NDA in preparation		
	Bronchitol for bronchiectasis: •I	Phase III trial in progress		
	ASM8 for asthma:	Phase II trial in progress		
Discovery	PXS25 (M6P receptor blocker); SSAO/VAP1 inhibitor			
Listing	ASX (Nov 2003): PXS			
Locations	Sydney, Australia • Philadelphia, USA • London, UK			
Facility	Manufacture of Aridol & Bronchito	ol		
Employees	129 (30/9/11)			
Cash	A\$34 million (30/9/11)			
Shares & Options	Shares outstanding: 229m; Options outstanding: 12m (30/9/11)			
Analyst coverage	SHAW STOCKBROKING A subsidiary of Bank of America Corporation CREDITS CREDITS	Suisse ** RBS Morgans WilsonHTM		





Cystic Fibrosis






Background

- Genetic disorder affecting 48,000 in EU and 30,000 in US
- Poorly hydrated, tenacious, thick mucus
- Average life expectancy at birth today in the US is 37 years

Current Therapies




- rhDNase (Pulmozyme[®]): global sales ~US\$540m (2010)
- Tobramycin (Tobi[®]): global sales ~US\$300m (2009)
- Aztreonam (Cayston®): approved EU: 9/09; US: 02/10



Progression of CF Lung Disease bronchitol






Clearance of thick mucus



Before treatment




Lung surface dehydrated

Airway surface fluid layer impaired

Lung defense and hygiene compromised

After Bronchitol administration



Lung hydrated

Airway surface liquid restored

Improved lung clearance

pharmaxis

Bronchitol

- Portable
 - No nebuliser
 - No refrigeration
- 3-5 minute treatment
 - Minimal set-up
 - Minimal cleaning
 - Minimal maintenance
- Hygienic
 - Weekly disposable device, no sterilisation
- Discreet
 - Inhaler is convenient and unobtrusive
 - No power source





Cystic Fibrosis clinical program





Two Pivotal Phase III trials – same design

- Multicentre, double blind, controlled
- Approx 300 subjects greater than 6 years old per trial
- 6 month treatment, 400mg twice per day followed by 6 month open label
- Primary endpoint:
 - lung function (FEV₁)
- Secondary endpoints:
 - Other lung function measures
 - Mucus clearance
 - Exacerbations
 - Antibiotic use
 - · QOL and safety
- CF301: 40 centres in UK, Ireland, Australia & New Zealand
- CF302: 53 centres in US, Canada, Argentina, Germany, France, Belgium, & Netherlands
- Subjects remain on existing best standard of care



Improvements in lung function



Change in lung function after <u>6 months</u> Bronchitol treatment


	Results of Clinical Trials CF301 and CF302 - Combined					
	Paediatric (6-11yrs)	Adolescents (12-17 yrs)	Adults (≥18 yrs)	Overa	II	
	FEV ₁	FEV ₁	FEV ₁	FEV ₁	p value	
% difference versus control (mL)	4.16	1.25	4.88	3.80	<0.001	
% change from baseline (mL)	13.19	8.41	4.68	7.32	<0.001	

Overall treatment response (FEV₁) over 26-weeks – all age groups (Pooled Data)

Sustained treatment effect



Change in lung function after 12 months Bronchitol treatment



CF301 and CF302 – Double Blind for 6 months followed by Open Label for 6 months

Exacerbation incidence reduced bronchitol





Percentage reduction in exacerbation incidence after 6 months Bronchitol treatment

CF301	35%	p=0.045
CF302	20%	p>0.05
CF301 +CF302 combined	29%	p=0.039





Commercialisation - Europe




- Orphan drug: 10-11 years market exclusivity
- Marketing approval status
 - Positive CHMP opinion received
 - Indicated for patients 18 years and older
 - Indicated as add on therapy to best standard of care
 - Anticipated European Commission approval Jan 12
- Clinical trial to be conducted in patients under 18
 - Design to be finalised after scientific advice from EMA

Cystic Fibrosis - Europe



CF Patients in Top 5 EU Countries


CF Patients			
Top 5 France, Germany, Italy, Spain, UK	30,000		
Western EU – other	10,000		
Central / Eastern EU	8,000		
Total EU	48,000		




Adult CF population represents major clinical need



CF patients in EU by age



Median FEV₁ Percent Predicted




Source: UK CF Registry

Pricing and reimbursement



Market access strategy for Bronchitol based on multiple information sources:





Targeted launch sequence


Country		Reimbursement process	Targeted launch date (CY)
	United Kingdom	Automatic reimbursement but significant national pricing guidance through NICE.	Q2 2012
2	Germany	Reimbursement granted with Marketing Authorisation	Q2 2012
T0P	France	Centralised & robust	Q4 2012
	Italy	Centralised with regional implementation	Q1 2013
	Spain	Centralised with regional implementation	Q3 2013
	Rest of Western Europe	Country dependent	Q3 2012 – Q3 2013
	Central & Eastern Europe	Country dependent	From Q3 2013 onwards

Existing physician awareness survey conducted H1 2010




Survey of Bronchitol awareness by country

Indicative prescription of Bronchitol by country



Q6: Please consider the list of emerging CF-specific treatments below. For each treatment, please indicate the statement that best reflects your level of awareness.



P49: If the following emerging therapies for cystic fibrosis (including Bronchitol) were currently available on the market, which, if any, would you consider prescribing to this patient?

Engagement with EU CF centres and clinicians



	Total	Other EU	Top 5	UK	Germany	Spain	Italy	France
Number of CF centres			294	48	110	35	34	67
Centres participating in clinical trials	46	6	40	24	4	-	-	12
Centres supporting consensus statement sent to CHMP	45	13	32	6	6	1	5	14
KoL's signed Consensus Statement	66	22	44	12	7	1	9	15
Clinicians attended international PXS symposia	344	169	175	110	32	9	11	13
PXS Advisory Boards with KoL's		X		X	X			
Contacts with patient organisations		X		X	X			

Other activities

- Pharmaco-economic models completed
- Reimbursement dossiers completed for NICE and French authorities.
- Exemption from new German process obtained
- Sales team development/recruitment underway in UK and Germany



Direct sales resources required

	Country	Sales Force Personnel	Centres/Sales Person
	United Kingdom	6	8
2	Germany	5	22
TOP	France	5	13
	Italy	4	9
	Spain	3	12
	Rest of Western Europe	7	N/A
	Central & Eastern Europe	Distributor strategy	Distributor strategy

European infrastructure



- UK Pharmaxis UK subsidiary and sales force in place (currently promoting Aridol)
- Remainder Western Europe (13 countries) Quintiles:
 - Recruit and manage dedicated Pharmaxis sales force
 - Local market knowledge to speed access
 - Full back office support
 - Satellite model leveraging PXS Top 5 country management infrastructure
- European CF market support Pharmaxis UK subsidiary
 - Marketing
 - Pricing
 - Medical information, regulatory and pharmacovigilance
- Build to total ~40 people in EU for CF
- Logistics infrastructure by 3rd party

US Cystic Fibrosis opportunity





Regulatory

- NDA scheduled submission H1 2012
- Earliest FDA review completed H1 2013
- Orphan drug provides 7 years market exclusivity



Marketing

- 150 CF centres anticipated to require 15 25 person field force
- 30,000 people in the US with CF
- Pulmozyme price ~US\$22,000 pa





Bronchitol - bronchiectasis



Abnormal, irreversible dilation of the lower airways



- Daily mucus production, constant coughing, breathlessness, recurrent acute bronchitis with infective exacerbations, low quality of life
- In 30-50% of cases, the cause is unknown
- Normal lung clearance impaired





No drugs proven effective to clear mucus



Bronchitol - bronchiectasis

Indication	Bronchiectasis (non Cystic Fibrosis)
Target Product Profile	Effective clearance of mucusReduction in exacerbation incidence
Market Size	Affects approximately 600,000 people worldwide
Competitors	Antibiotics & CF drugs; lack of targeted clinical development in this disease state
Status	Phase III trial recruitment ongoing
Next Milestone	Close of recruitment in Phase III trial – Q4 2011 - 474 subjects, 89 sites in US, Europe, South America & Australia

Aridol®


- Identifies airway hyperresponsiveness which helps physicians in the overall assessment of asthma
- An easy-to-use test kit provides rapid results and doesn't require specialized equipment





Aridol – commercialisation status







Potential growth

- US and Korea
- Asthma management
- COPD



Development Pipeline



Aridol – asthma (Aus/EU/Korea/USA)

Bronchitol – cystic fibrosis (Aus)

Bronchitol – cystic fibrosis (EU)

Bronchitol – cystic fibrosis (US)


Bronchitol – bronchiectasis (US/EU)

Bronchitol - other

ASM8 - asthma

PXS25 – lung fibrosis

SSAO inhibitors – lung disease



ASM8 – Asthma

Indication	Moderate to severe asthma for patients who do not respond to inhaled steroids or cannot tolerate high doses
Target Product Profile	 Greater efficacy through multi-targeting Better tolerability & convenience compared with current treatments Once daily nebulisation
Market Size	Affects approx 12 million people worldwide
Competitors	Singulair (US\$4.5B sales, 2008), Xolair (US\$730M sales, 2008)
Status	Phase II trial ongoing
Next Milestone	Phase II trial results anticipated – Q1 2012

PXS25 - IPF

Indication	Idiopathic Pulmonary Fibrosis (IPF)	
Target Product Profile	 Inhibition of fibrosis and inflammation to lung tissue Local administration to the lung Safe & well tolerated in humans 	
Market Size	Affects approx 90,000 people in the USA	
Competitors	Pirfenidone (just launched in EU), immunosuppressives & steroids	
Status	Phase I trial complete	
Next Milestone	Phase II trial planning – Q1 2012	

SSAO – Lung inflammation

Indication	Treatment of inflammatory disease, such as asthma
Target Product Profile	Target eosinophilic and neutrophilic asthmaOnce daily oral dosing
Market Size	Affects approx 20 million people worldwide
Competitors	All in pre-clinical development
Status	Pre-clinical development
Next Milestone	Lead development candidate – Q4 2011

Financial Statements

Financial Statement Data - Unaudited

(International Financial Reporting Standards)

('000 except per share data)


Income Statement Data	Three months ended
	30-Sep-11 30-Se
	A\$ A\$
Revenue from sale of goods	319 202
Cost of sales	(122) (69)
Gross profit	197 133
Interest	450 937
Other income	74 175
Expenses	
Research & development	(7,221) (8,768)
Commercial	(1,736) (1,469)
Administration	(913) (1,197)
Finance expenses	(210) (290)
Total expenses	(10,080) (11,724)
Loss before income tax	(9,359) (10,479)
Income tax expense	
Loss for the period	(9,359) (10,486)
Basic and diluted earnings (loss) per share - \$	(0.041) (0.046)
Depreciation & amortisation	1,178 1,189
Fair value of securities issued under employee plans	243 440

Financial Statements

Balance Sheet Data		As at	
	30-Sep-11	30-Jun-11	
	A\$	A\$	
Cash and cash equivalents	33,730	44,343	
Property, plant & equipment	29,757	30,570	
Intangible assets	15,475	15,954	
Total assets	82,955	94,572	
Total liabilities	(21,046)	(23,742)	
Net assets	61,908	70,830	
Cash Flow Data	Three month	s ended	
	30-Sep-11	30-Sep-10	
	A\$	A\$	
Cash flows from operating activities	(10,657)	(8,795)	
Cash flows from investing activities	84	(433)	
Cash flows from financing activities	(120)	(288)	
Impact of foreign exchange rate movements on cash	79	(440)	
Net increase (decrease) in cash held	(10,614)	(9,956)	
Share Data	Ordinary Sha	Ordinary Shares as at	
	30-Sep-11	30-Jun-11	
Ordinary shares on issue	229,116	225,765	
Options over ordinary shares outstanding	11,989	13,297	

Share Capital

(including options)



Summary

- Respiratory company with approved products and strong pipeline
- Aridol
 - approved in Australia, SEA, Europe and USA
- Bronchitol
 - approved in Australia for cystic fibrosis
 - Going through pricing / reimbursement
 - recommended for approval in Europe
 - First launch expected 1H 2012
 - USA marketing application to be filed 1H 2012
 - Clinical trials in progress to expand opportunity
- ASM8 for asthma
 - In Phase II

pharmaxis End